These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 1656759)

  • 1. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
    Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
    Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymerase chain reaction/sequencing analysis of ras mutations in paraffin-embedded tissues as compared with 3T3 transfection and polymerase chain reaction/sequencing of frozen tumor deoxyribonucleic acids.
    Goodrow TL; Prahalada SR; Storer RD; Manam SV; Leander KR; Kraynak AR; van Zwieten MJ; Nichols WW; Bradley MO
    Lab Invest; 1992 Apr; 66(4):504-11. PubMed ID: 1583889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
    Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
    Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
    Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
    Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras activation in neoplasms of the human female reproductive tract.
    Enomoto T; Inoue M; Perantoni AO; Terakawa N; Tanizawa O; Rice JM
    Cancer Res; 1990 Oct; 50(19):6139-45. PubMed ID: 2205377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ras mutations and expression in head and neck squamous cell carcinomas.
    Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
    Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
    Goodrow T; Reynolds S; Maronpot R; Anderson M
    Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations.
    Kabbani W; Houlihan PS; Luthra R; Hamilton SR; Rashid A
    Mod Pathol; 2002 Jun; 15(6):599-605. PubMed ID: 12065772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.